|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
CA 15.3 Cancer Antigen
Test CodeCA153
Alias/See Also
CA153, CA2729, or Cancer antigen, breast
CPT Codes
86300
Preferred Specimen
1.0 mL of whole blood (0.5 mL of serum/plasma)
Minimum Volume
0.6 mL of whole blood (0.3 mL of serum/plasma)
Transport Container
Serum Separator (gold top) or No Additive Red Top. Lithium Heparin (mint or green top), EDTA (lavendar top)
Transport Temperature
Refrigerated
Specimen Stability
Room Temperature: 8 hours
Refrigerated: 7 days
Frozen: 4 weeks at - 20 C
Refrigerated: 7 days
Frozen: 4 weeks at - 20 C
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Turbid specimens are unacceptable.
Methodology
Chemiluminescent
Setup Schedule
Set up Monday through Saturday.
Report Available
Specimens received by noon will be reported by 4:30 p.m. Specimens received after noon will be reported by the next morning
Clinical Significance
Research studies have indicated that CA 15-3 assay values are frequently elevated in patients with breast cancer. These studies have suggested that the CA 15-3 assay may be of clinical value for monitoring the response of patients undergoing therapy because increasing and decreasing values correlated with disease progression and regression, respectively. Additional published studies have suggested that increasing CA15-3 assay values
in patients at risk for breast cancer recurrence after primary therapy may be indicative of recurrent disease before it can be detected clinically.
The CA 15-3 assay is not recommended as a screening procedure to detect cancer in the general population; however, use of the CA 15-3 assay as an aid in the management of breast cancer patients has been reported.
Values obtained with different assay methods or kits cannot be used interchangeably.
in patients at risk for breast cancer recurrence after primary therapy may be indicative of recurrent disease before it can be detected clinically.
The CA 15-3 assay is not recommended as a screening procedure to detect cancer in the general population; however, use of the CA 15-3 assay as an aid in the management of breast cancer patients has been reported.
Values obtained with different assay methods or kits cannot be used interchangeably.
